Shyam Bhaskaran

Shyam Bhaskaran

Interim Deputy Director, Regulatory Affairs

Shyam Bhaskaran leads the Integrated Development team’s Smart Safety Surveillance (3S) strategy to build functional pharmacovigilance systems in low- and middle-income countries to ensure patient safety as new global health products are launched. He also collaborates with the foundation’s Malaria team to create regional and continental frameworks for regulating the introduction of novel vector control technologies (such as gene drive). In previous roles at the foundation, he provided product development and global regulatory strategy advice to foundation teams and their product development partners and managed a portfolio of grants focused on optimizing regulatory systems in low- and middle-income countries.

Before joining the foundation in 2016, Shyam was a senior consulting manager at Quintiles (San Francisco), advising on R&D, clinical strategy and operations, data analytics, and innovation, and serving as a technical advisor on biosimilars and regenerative medicines. Earlier, he worked at PwC (New York City), where he was a senior associate in life sciences advisory. Before becoming a consultant, Shyam was a research biochemist. He helped design novel antibiotic leads and was part of a successful biotech startup focused on PEGgylated biologics, obtaining multiple patents and approval of one orphan drug.

Shyam holds a Ph.D. in structural biology and microbiology from the Rockefeller University in New York, a MBA from Cornell University, a M.S. in chemistry from San Francisco State University, and a B.Sc. (advanced) in biochemistry and chemistry from the University of Sydney.

More about the foundation

Our story

Learn about the origins of the foundation and the values that drive our work.

Our work

Learn about where we work around the globe and the programs we've created to address urgent issues in global health, global development, and education.


Read the latest stories, research, and news from across the foundation and subscribe to our weekly newsletter, The Optimist.